0001104659-19-015619.txt : 20190318
0001104659-19-015619.hdr.sgml : 20190318
20190318164028
ACCESSION NUMBER: 0001104659-19-015619
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190314
FILED AS OF DATE: 20190318
DATE AS OF CHANGE: 20190318
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Malik Usama
CENTRAL INDEX KEY: 0001737803
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 19688756
MAIL ADDRESS:
STREET 1: 300 THE AMERICAN WAY
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
4
1
a4.xml
4
X0306
4
2019-03-14
0
0000722830
IMMUNOMEDICS INC
IMMU
0001737803
Malik Usama
C/O IMMUNOMEDICS, INC.
300 THE AMERICAN ROAD
MORRIS PLAINS
NJ
07950
0
1
0
0
Chief Financial & Business OFF
Stock Option (right to buy)
17.94
2019-03-14
4
A
0
51320
0
A
2026-03-14
Common Stock, par value $0.01 per share
51320
51320
D
Stock Option (right to buy)
17.94
2019-03-14
4
A
0
25660
0
A
2026-03-14
Common Stock, par value $0.01 per share
25660
25660
D
The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter.
The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant.
/s/ Usama Malik
2019-03-18